JP2021514654A5 - - Google Patents
Info
- Publication number
- JP2021514654A5 JP2021514654A5 JP2020545669A JP2020545669A JP2021514654A5 JP 2021514654 A5 JP2021514654 A5 JP 2021514654A5 JP 2020545669 A JP2020545669 A JP 2020545669A JP 2020545669 A JP2020545669 A JP 2020545669A JP 2021514654 A5 JP2021514654 A5 JP 2021514654A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- region contains
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1803226.8A GB201803226D0 (en) | 2018-02-28 | 2018-02-28 | CSF1R Binding agents |
| GB1803226.8 | 2018-02-28 | ||
| GBGB1810226.9A GB201810226D0 (en) | 2018-02-28 | 2018-06-21 | CSF1R binding agents |
| GB1810226.9 | 2018-06-21 | ||
| GB1819045.4 | 2018-11-22 | ||
| GBGB1819045.4A GB201819045D0 (en) | 2018-02-28 | 2018-11-22 | Csf1r binding agents |
| PCT/EP2019/055077 WO2019166596A1 (en) | 2018-02-28 | 2019-02-28 | Csf1r binding agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021514654A JP2021514654A (ja) | 2021-06-17 |
| JP2021514654A5 true JP2021514654A5 (enExample) | 2022-03-09 |
Family
ID=61903334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020545669A Pending JP2021514654A (ja) | 2018-02-28 | 2019-02-28 | Ｃｓｆ１ｒ結合剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11655300B2 (enExample) |
| EP (1) | EP3759137A1 (enExample) |
| JP (1) | JP2021514654A (enExample) |
| CN (1) | CN111788229A (enExample) |
| AU (1) | AU2019228110A1 (enExample) |
| CA (1) | CA3091307A1 (enExample) |
| GB (3) | GB201803226D0 (enExample) |
| IL (1) | IL276914A (enExample) |
| SG (1) | SG11202007837RA (enExample) |
| WO (1) | WO2019166596A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240002509A1 (en) * | 2020-11-06 | 2024-01-04 | Novartis Ag | ANTIBODY Fc VARIANTS |
| CN112472790B (zh) * | 2020-12-25 | 2022-12-20 | 同济大学 | 小白蛋白的抑制剂在制备预防治疗肥胖以及肥胖导致的疾病产品中的用途 |
| CN119019548B (zh) * | 2022-07-05 | 2025-06-24 | 东莞市朋志生物科技有限公司 | 抗甲型流感病毒抗体、检测甲型流感病毒的试剂和试剂盒 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0909044B8 (pt) | 2008-03-14 | 2021-05-25 | Transgene Sa | anticorpo que se liga especificamente ao csf-1r humano,composição farmacêutica e uso dos mesmos |
| AR080698A1 (es) * | 2010-04-01 | 2012-05-02 | Imclone Llc | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| KR20140127855A (ko) * | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| GB201315487D0 (en) * | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
-
2018
- 2018-02-28 GB GBGB1803226.8A patent/GB201803226D0/en not_active Ceased
- 2018-06-21 GB GBGB1810226.9A patent/GB201810226D0/en not_active Ceased
- 2018-11-22 GB GBGB1819045.4A patent/GB201819045D0/en not_active Ceased
-
2019
- 2019-02-28 AU AU2019228110A patent/AU2019228110A1/en not_active Withdrawn
- 2019-02-28 SG SG11202007837RA patent/SG11202007837RA/en unknown
- 2019-02-28 EP EP19709003.8A patent/EP3759137A1/en not_active Withdrawn
- 2019-02-28 WO PCT/EP2019/055077 patent/WO2019166596A1/en not_active Ceased
- 2019-02-28 JP JP2020545669A patent/JP2021514654A/ja active Pending
- 2019-02-28 CN CN201980015847.8A patent/CN111788229A/zh active Pending
- 2019-02-28 US US16/976,196 patent/US11655300B2/en active Active
- 2019-02-28 CA CA3091307A patent/CA3091307A1/en active Pending
-
2020
- 2020-08-25 IL IL276914A patent/IL276914A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021515541A5 (enExample) | ||
| JP2021519100A5 (enExample) | ||
| JP2021513323A5 (enExample) | ||
| JP2021515542A5 (enExample) | ||
| JP7734753B2 (ja) | 抗ｃｌｄｎ６抗体およびその使用 | |
| JP2024513921A5 (enExample) | ||
| JP2022553908A5 (enExample) | ||
| JP2017149720A5 (enExample) | ||
| JP2021514664A5 (enExample) | ||
| JP2020514277A5 (enExample) | ||
| CN107151269A (zh) | 一种pdl‑1抗体、其药物组合物及其用途 | |
| JP2021516537A5 (enExample) | ||
| FI4041763T3 (fi) | Pd1:tä ja vegfr2:ta kaksoissitovia aineita | |
| HRP20200583T1 (hr) | Protutijela koja neutraliziraju gp120 i njihova upotreba | |
| JP2018506961A5 (enExample) | ||
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| JP2020521504A (ja) | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 | |
| JP2024540148A5 (enExample) | ||
| JP2021534797A5 (enExample) | ||
| JP2021515544A5 (enExample) | ||
| JP2020513759A5 (enExample) | ||
| RU2019135404A (ru) | Антитела для лечения инфекции гепатитом в и связанных с ней заболеваний | |
| JP2021514654A5 (enExample) | ||
| JP2023542209A5 (enExample) | ||
| JP2025511288A5 (enExample) |